AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Vertex Pharmaceuticals Inc

Healthcare US VRTX


Last update at 2024-05-21T18:51:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 4232.40M 2730.40M 3116.80M 1394.92M 600.24M
Minority interest - - 0.00000M 0.00000M -9.79300M
Net income 3322.00M 2342.10M 2711.65M 1176.81M 2096.90M
Selling general administrative 887.20M 840.10M 770.46M 658.50M 557.62M
Selling and marketing expenses - - - - -
Gross profit 7850.40M 6670.20M 5469.38M 3615.06M 2638.06M
Reconciled depreciation 148.30M 125.60M 109.52M 106.94M 72.42M
Ebit 4307.40M 2782.10M 2856.29M 1197.57M 590.76M
Ebitda 4345.20M 2788.80M 3188.05M 1457.88M 663.18M
Depreciation and amortization 37.80M 6.70M 331.76M 260.31M 72.42M
Non operating income net other -20.20000M 9.80M 318.66M 255.85M -0.79000M
Operating income 4307.40M 2782.10M 2856.29M 1197.57M 635.15M
Other operating expenses 4565.30M 4795.40M 3336.29M 2960.80M 2383.63M
Interest expense 54.80M 61.50M 58.15M 58.50M 34.12M
Tax provision 910.40M 388.30M 405.15M 218.11M -1486.86200M
Interest income 144.60M 4.90M 22.24M 63.68M 33.50M
Net interest income 89.80M -56.60000M -35.91200M 5.18M -34.11900M
Extraordinary items - - - - 1560.00M
Non recurring 115.50M - - - 28.82M
Other items - - - - -
Income tax expense 910.40M 388.30M 405.15M 218.11M -1486.86200M
Total revenue 8930.70M 7574.40M 6205.68M 4162.82M 3047.60M
Total operating expenses 3485.00M 3891.20M 2599.99M 2413.04M 1974.09M
Cost of revenue 1080.30M 904.20M 736.30M 547.76M 409.54M
Total other income expense net -75.00000M -51.70000M 260.51M 197.35M -29.60600M
Discontinued operations - - - - -
Net income from continuing ops 3322.00M 2342.10M 2711.65M 1176.81M 2087.10M
Net income applicable to common shares 3322.00M 2342.10M 2711.65M 1176.81M 2096.90M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 18150.90M 13432.50M 11751.81M 8318.47M 6245.90M
Intangible assets 603.60M 400.00M 400.00M 400.00M 50.38M
Earning assets - - - - -
Other current assets 74.40M 187.20M 308.35M 213.51M 74.05M
Total liab 4238.20M 3332.50M 3064.99M 2233.22M 1810.69M
Total stockholder equity 13912.70M 10100.00M 8686.82M 6085.24M 4435.20M
Deferred long term liab - - - - -
Other current liab 1877.70M 1460.00M 1171.02M 1024.29M 40.59M
Common stock 2.60M 2.50M 2.60M 2.59M 2.55M
Capital stock 2.60M 2.50M 2.60M 2.59M 2.55M
Retained earnings 6522.80M 3200.80M 858.67M -1852.97800M -2989.47800M
Other liab 685.80M 902.20M 923.41M 275.53M 108.85M
Good will 1088.00M 1402.20M 1402.16M 1402.16M 50.38M
Other assets 1422.70M 986.90M 587.03M 1199.40M 1540.40M
Cash 10504.00M 6795.00M 5988.19M 3109.32M 2650.13M
Cash and equivalents - - - - -
Total current liabilities 2430.60M 1873.60M 1560.11M 1204.52M 715.48M
Current deferred revenue 159.60M 171.70M 191.52M 62.33M 554.09M
Net debt -9943.00000M -6238.30000M -5406.71100M -2531.95100M -2082.97100M
Short term debt 89.40M 46.90M 42.43M 30.29M 9.82M
Short long term debt - - - - -
Short long term debt total 561.00M 556.70M 581.48M 577.37M 567.16M
Other stockholder equity 7386.50M 6880.80M 7894.03M 7937.61M 7421.48M
Property plant equipment 1455.80M 1094.10M 958.53M 833.28M 812.00M
Total current assets 12681.30M 9014.80M 7825.03M 4609.31M 3702.29M
Long term investments - - - 60.80M 13.60M
Net tangible assets 12221.10M 8697.80M 7284.66M 4683.09M 4384.82M
Short term investments 274.50M 729.90M 670.71M 698.97M 518.11M
Net receivables 1442.20M 1136.80M 885.35M 633.52M 409.69M
Long term debt - - - - 561.89M
Inventory 460.60M 353.10M 280.78M 167.50M 124.36M
Accounts payable 303.90M 195.00M 155.14M 87.61M 110.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.80M 15.90M -68.48000M -1.97300M 0.66M
Additional paid in capital - - - - -
Common stock total equity 2.60M 2.50M 2.60M 2.59M 2.55M
Preferred stock total equity - - - - -
Retained earnings total equity 6522.80M 3200.80M 858.67M -1852.97800M -2989.47800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1422.70M 986.90M 683.31M 371.10M 181.55M
Deferred long term asset charges - - - - -
Non current assets total 5469.60M 4417.70M 3926.78M 3709.15M 2543.61M
Capital lease obligations 471.60M 556.70M 581.48M 538.58M 19.66M
Long term debt total - - 539.04M 538.58M 581.55M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 227.30M -28.90000M 378.51M 33.66M -15.34200M
Change to liabilities 1162.20M 354.10M 598.57M 188.09M 232.18M
Total cashflows from investing activities -321.10000M -340.90000M 99.39M -1235.31800M -202.15800M
Net borrowings -85.50000M -24.40000M -29.02400M -35.00500M -7.08600M
Total cash from financing activities -67.70000M -1478.00000M -505.28100M 126.77M -71.21900M
Change to operating activities 715.00M 230.40M 249.73M 246.32M 341.58M
Net income 3322.00M 2342.10M 2711.65M 1176.81M 2087.10M
Change in cash 3711.90M 811.20M 2868.16M 462.43M 990.73M
Begin period cash flow 6800.10M 5988.90M 3120.68M 2658.25M 1667.53M
End period cash flow 10512.00M 6800.10M 5988.85M 3120.68M 2658.25M
Total cash from operating activities 4129.90M 2643.50M 3253.51M 1569.33M 1270.29M
Issuance of capital stock - - - 343.24M 289.29M
Depreciation 148.30M 125.60M 109.52M 106.94M 72.42M
Other cashflows from investing activities -343.70000M -77.00000M -19.32700M -1193.53100M -91.29200M
Dividends paid - -102.00000M -264.94600M -10.04600M 20.84M
Change to inventory -136.40000M -92.80000M -132.01400M -64.04700M -31.96500M
Change to account receivables -358.60000M -274.70000M -223.44400M -225.58700M -108.15200M
Sale purchase of stock -172.00000M -1561.30000M -739.40700M -192.01500M -350.04300M
Other cashflows from financing activities 3.50M 130.30M 276.40M 24.77M 43.76M
Change to netincome 445.60M 452.70M 521.39M 381.89M 385.07M
Capital expenditures 204.70M 235.00M 259.80M 75.45M 95.52M
Change receivables -358.60000M -274.70000M -223.44400M -225.58700M -108.15200M
Cash flows other operating -453.20000M -263.50000M -332.15800M 5.23M -1366.36500M
Exchange rate changes - - - - -6.18200M
Cash and cash equivalents changes 3741.10M 824.60M 2847.61M 460.79M 990.73M
Change in working capital 340.80M -105.20000M -54.45400M -66.10100M 238.02M
Stock based compensation 491.30M 441.40M 429.46M 360.49M 325.05M
Other non cash items 103.40M -5.80000M -220.00500M -176.19600M 60.02M
Free cash flow 3925.20M 2408.50M 2993.70M 1493.88M 1174.76M


  • Previous Close 445.87
  • Market Cap104426.04M
  • Volume496648
  • P/E Ratio30.40
  • Dividend Yield-%
  • EBITDA4570.10M
  • Revenue TTM9654.20M
  • Revenue Per Share TTM37.49
  • Gross Profit TTM 5323.10M
  • Diluted EPS TTM13.33

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Vertex Pharmaceuticals Inc
-6.66 1.49% 439.21 30.40 24.75 10.68 6.25 9.52 20.36
Novo Nordisk A/S
1.63 1.23% 134.54 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
1.54 1.16% 134.67 41.06 31.25 2.08 33.11 2.11 4.70
-0.16 0.17% 92.58 42.45 26.95 7.05 5.80 7.85 26.51
CSL Limited
-3.835 2.07% 181.79 41.30 26.39 6.97 5.68 7.85 26.51

Reports Covered

Stock Research & News


Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc

50 Northern Avenue, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Dr. Jeffrey Marc Leiden M.D., Ph.D. Exec. Chairman 1956
Dr. Reshma Kewalramani FASN, M.D. CEO, Pres & Director 1973
Mr. Charles F. Wagner Jr. Exec. VP & CFO 1968
Mr. Stuart A. Arbuckle B.Sc. Exec. VP & COO 1966
Dr. Ourania Tatsis Ph.D. Exec. VP and Chief Regulatory & Quality Officer 1971
Ms. Kristen C. Ambrose Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services 1977
Dr. David M. Altshuler M.D., Ph.D. Exec. VP of Global Research & Chief Scientific Officer 1965
Mr. Mike Tirozzi SVP and Chief Information & Data Officer NA
Susie Lisa Sr. VP of Investor Relations NA
Mr. Damian W. Wilmot Esq. Sr. VP, Chief Risk and Compliance Officer 1976

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).